Skip to main content
Equibles

Terrance Coyne

CFO

Royalty Pharma plc (RPRX)

Equibles does not estimate personal net worth.

Get an email with a short summary when Royalty Pharma plc publishes a filing, an earnings call transcript or a press release.

Get RPRX alerts

About Terrance Coyne

Terrance Coyne is recorded as CFO at Royalty Pharma plc (RPRX). The newest filing on record that lists Terrance Coyne as CFO at Royalty Pharma plc (RPRX) is dated April 10, 2026. The proxy statement of Royalty Pharma plc reports total compensation of $1,323,000 for Terrance Coyne in fiscal 2025, including a base salary of $1,323,000. Disclosed compensation is on record for 3 fiscal years. Terrance Coyne has spoken on 6 earnings calls across 1 company, most recently for Royalty Pharma plc on August 6, 2025. Royalty Pharma plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Royalty Pharma plc includes Pablo Legorreta (CEO), Vlad Coric (CEO and Board Member), Christopher Hite (Chairman) and 7 others.

Terrance Coyne on recent calls

“This slide shows how our efficient business model generates substantial cash flow to be reinvested. As you heard from Pablo, Royalty Receipts grew by 11% in the second quarter, reflecting the strength of our diversified portfolio.”
CFO, Royalty Pharma plc Q2 FY2025 Earnings Call ·
“This slide shows how our efficient business model generates substantial cash flow to be reinvested. Royalty Receipts grew by 12% in the fourth quarter and 13% for the year, reflecting the strength of our diversified portfolio.”
CFO, Royalty Pharma plc Q4 FY2024 Earnings Call ·
“Royalty Receipts grew by 14% in the first quarter, reflecting the strength of our diversified portfolio. The key drivers of growth were the strong performance of our base business, notably our cystic fibrosis franchise and Trelegy, as well as the acquisition of incremental Evrysdi royalties.”
CFO, Royalty Pharma plc Q1 FY2024 Earnings Call ·
“You'll have seen from our press release today that we have made changes to our financial presentation in order to enhance transparency and disclosures for investors, and to better reflect the nature of our cash flows.”
CFO, Royalty Pharma plc Q4 FY2023 Earnings Call ·
“Total Royalty receipts grew 5% in the third quarter versus the year-ago period. Excluding the Biohaven-related payment in the prior year period, Royalty receipts grew approximately 7%.”
CFO, Royalty Pharma plc Q3 FY2023 Earnings Call ·

Affiliation history

Company network

Leadership on record at Royalty Pharma plc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Royalty Pharma plc (RPRX) $1,323,000 $1,323,000
2024 Royalty Pharma plc (RPRX) $1,260,000 $1,260,000
2023 Royalty Pharma plc (RPRX) $1,200,000 $4,560,000

Recent activity